Abivax’s $920M Cash War Chest Fuels Solo U.S. Launch Plan

The company’s Paris-listed shares have surged more than 1,600% over the past year, though the path has been rocky. A late-stage trial for obefazimod in ulcerative colitis patients reported cancer cases in the study cohort, sending shares down sharply as analysts questioned the drug’s commercial viability. A second dataset from the same trial showed malignancy rates were consistent with normal expectations for the patient demographic, helping shares recover.

De Garidel emphasized the drug’s “unmatched efficacy for the drug in a hard-to-treat population” and repeated the company’s stance that it is safe. “When you have ulcerative colitis, unfortunately, your immune system is depleted, and you are more susceptible to a certain type of cancer,” he said.

Abivax will meet with the U.S. Food and Drug Administration at the end of July to discuss its New Drug Application for obefazimod, a pre-NDA meeting.

Takeover speculation has surrounded the company since it reported strong eight-week efficacy data in July 2025. A subsequent 44-week “maintenance” trial supported the profile. Analysts have modelled a potential acquisition price as high as $23 billion and said Abivax could be a strategic fit for any large pharma with an immunology and inflammation franchise.